Featured news from NHIVNA
HIV-related news from NAM
Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients
Liz Highleyman, 2014-04-11 07:20:00
A coformulation of sofosbuvir and ledipasvir successfully treated a variety of difficult-to-treat patient populations including people with hepatitis C virus (HCV) genotype 3, patients with decompensated cirrhosis and people who were not cured with previous sofosbuvir-containing therapy, according to a series of studies presented Thursday at the 49th EASL International Liver Congress in London.
Edward Gane of Auckland Clinical Studies in New Zealand presented results from ELECTRON-2, an analysis of the safety and efficacy of a once-daily fixed-dose combination pill containing the recently approved HCV polymerase inhibitor sofosbuvir (Sovaldi) plus the NS5A inhibitor ledipasvir (400mg/90mg) in three challenging populations.
Data from the phase 3 ION trials of the sofosbuvir/ledipasvir coformulation will be presented later at the International Liver Congress.
Source:1
